Automate Your Wheel Strategy on CELU
With Tiblio's Option Bot, you can configure your own wheel strategy including CELU - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CELU
- Rev/Share 2.4769
- Book/Share 0.4037
- PB 5.5488
- Debt/Equity 3.2854
- CurrentRatio 0.383
- ROIC -0.4707
- MktCap 53646208.0
- FreeCF/Share -0.2998
- PFCF -8.1753
- PE -0.6869
- Debt/Assets 0.2188
- DivYield 0
- ROE -3.3523
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Celularity Receives Nasdaq Notice Regarding Form 10-Q
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.
Read More
Celularity Announces Full Year 2024 Operating and Financial Results
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year.
Read More
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds
Read More
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy products.
Read More
About Celularity Inc. (CELU)
- IPO Date 2019-08-08
- Website https://www.celularity.com
- Industry Biotechnology
- CEO Dr. Robert Joseph Hariri M.D., Ph.D.
- Employees 120